id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-275772-pmf6stua	Jourdan, Jean‐Pierre	Drug repositioning: a brief overview	2020-04-17		.txt	text/plain	3239	160	43	Drug repositioning lies in repurposing an active pharmaceutical ingredient that is already on the market for a new indication. This original definition of drug repositioning has since been extended to include active substances that failed the clinical phase of their development on account of their toxicity or insufficient efficacy, as well as drugs withdrawn from the market because of safety concerns. Instead, repositioning makes use in a new indication of either the biological properties for which the drug has already been approved (possibly according to a different formulation, at a new dose or via a new route of administration), or the side properties of a drug that are responsible for its adverse effects. This example illustrates how even drugs with an exceptionally poor toxicity profile can be repositioned if the new indication is a rare disease (the estimated incidence of leprosy is 250 000 cases per year according to http://www.orpha.net, accessed November, 21th 2019). Drug repositioning: identifying and developing new uses for existing drugs	./cache/cord-275772-pmf6stua.txt	./txt/cord-275772-pmf6stua.txt